Product Description: Sonidegib diphosphate (Erismodegib diphosphate) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].
Applications: Cancer-programmed cell death
Formula: C26H32F3N3O11P2
Citations: J Genet Genomics. 2018 May 20;45(5):237-246./Nat Med. 2018 Nov;24(11):1752-1761. /Patent. US20180263995A1./bioRxiv. 2023 Nov 6./bioRxiv. 2024 Jul 25./bioRxiv. 2024 Oct 9:2024.10.08.617155./Cell Physiol Biochem. 2018;47(4):1352-1364./Tissue Cell. 2024 Nov 28:92:102643.
References: [1]Pan S, et al. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett. 2010 Mar 16;1(3):130-4./[2]Irvine DA, et al. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci Rep. 2016 May 9;6:25476.
CAS Number: 1218778-77-8
Molecular Weight: 681.49
Compound Purity: 99.73
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 0.25 mg/mL (ultrasonic)
Target: Smo
Deutsch
English
